Diabetes Core Update cover image

Diabetes Core Update – March 2023

Diabetes Core Update

00:00

Simaglotide and Cardiometabolic Risk

Greater weight loss was associated with greater improvements to cardiometabolic risk factors, particularly as you went from 5% weight loss to 20%. They also found very interestingly that some of the improvements appear to be independent of the weight loss. And I think that gives some credence to the previous studies that looked at GOP1 receptor agonist and the improvement in cardiovascular outcome in individuals with diabetes. It seems to be an independent pleurotrauffic effect.

Transcript
Play full episode

The AI-powered Podcast Player

Save insights by tapping your headphones, chat with episodes, discover the best highlights - and more!
App store bannerPlay store banner
Get the app